Randomized trial demonstrates improved prognostic stratification in advanced NSCLC, suggesting a better outcome prediction strategy.
Integrated radiogenomic models outperform clinical-only models in predicting OS and DFS in advanced NSCLC. High concordance (85%) was observed between tissue biopsy and ctDNA for molecular profiling at diagnosis. Baseline ctDNA status is a significant independent prognostic factor, particularly in EGFRmutant patients. Radiomic scores (RS) derived from standard CT scans provide independent prognostic value for survival outcomes. Longitudinal ctDNA monitoring effectively tracks response and disease progression during targeted therapy. ClinicalTrials.
No takes yet. Share an insight, caveat, or question.
Ranghiero et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: